Should I Buy ARTV? ARTV 2026 Analysis

Should You Buy Artiva Biotherapeutics Inc (ARTV) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

4.150

1 Day change

-7.16%

52 Week Range

7.360

Analysis Updated At

2026/01/28

ARTV is not a good buy right now for a Beginner, long-term investor with $50k–$100k who is impatient for results. Despite a short-term bullish moving-average setup, the lack of revenue, ongoing sizable losses, and no supportive proprietary trading signals make the risk/reward unattractive at the current ~$4.85 pre-market level (near resistance).

Technical Analysis

Price/Trend (pre-market ~$4.85, +2.47%): Trend is technically improving, but momentum is not convincingly positive. - Moving Averages: Bullish alignment (SMA_5 > SMA_20 > SMA_200) suggests an upward bias. - RSI(6) 59.16: Neutral-to-slightly bullish; not overbought. - MACD histogram -0.00598: Below zero and negatively contracting, implying upside momentum is weak/fragile. - Key levels: Pivot 4.663. Resistance R1 5.007 then R2 5.219. Support S1 4.319 then S2 4.107. With price ~4.85, upside is close to R1, while downside to S1 is meaningful. - Pattern-based odds: Next day small upside bias (+0.68%), next week bearish (-4.24%), next month bullish (+11.45%)—mixed and not ideal for an impatient buyer. **Intellectia Proprietary Trading Signals** - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.

Options Data

Positive Catalysts

- Bullish moving-average structure (SMA_5 > SMA_20 > SMA_200) supports a constructive technical backdrop.
- Pre-market strength (+2.47%) may indicate near-term interest.
- Upcoming earnings event (QDEC 2025) on 2026-02-11 after hours could act as a catalyst if results/surprises are favorable.

Neutral/Negative Catalysts

- No news in the recent week—no clear positive event-driven catalyst currently supporting a sustained move.
- Momentum confirmation is lacking (MACD histogram still below zero).
- Price is approaching near resistance (R1 ~5.01), limiting immediate upside versus downside to support.
- Micro-cap profile (market cap ~$119M) combined with weak fundamentals increases uncertainty for long-term beginners.
- Next-week pattern outlook is negative (-4.24%), which conflicts with an impatient entry.

Financial Performance

Latest reported quarter: 2025/Q3. - Revenue: 0 (no meaningful revenue base). - Net income: -$21.528M, improved 23.21% YoY (loss narrowing), but still deeply negative. - EPS: -0.88, down 4.35% YoY (slightly worse). - Gross margin: 0, down 100% YoY. Overall: Financials do not show operating traction; improvements are mostly loss-narrowing, not growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating/price target change data was provided, so there is no observable recent trend in upgrades/downgrades or target revisions. From the available dataset, Wall Street pro/con positioning cannot be confirmed; absent coverage is effectively a neutral-to-negative signal for a beginner long-term allocation.

5 Analyst Rating

Wall Street analysts forecast ARTV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARTV is 16.5 USD with a low forecast of 10 USD and a high forecast of 23 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 4.470

Low

Averages

16.5

High

Current: 4.470

Low

Averages

16.5

High

Wedbush

Outperform

maintain

$18 -> $23

AI Analysis

2025-10-17

Reason

Wedbush

Price Target

$18 -> $23

AI Analysis

2025-10-17

maintain

Outperform

Reason

Wedbush raised the firm's price target on Artiva Biotherapeutics to $23 from $18 and keeps an Outperform rating on the shares. The firm notes the company announced refractory rheumatoid arthritis as the lead indication for AlloNK and announced FDA Fast Track Designation, with pivotal development possible as early as 2026 pending regulatory discussions. Importantly, the development program will feature low-dose lymphodepletion to maximize B cell depletion while minimizing adverse impacts among this patient population.

H.C. Wainwright

Emily Bodnar

Buy

initiated

$12

2025-06-11

Reason

H.C. Wainwright

Emily Bodnar

Price Target

$12

2025-06-11

initiated

Buy

Reason

H.C. Wainwright analyst Emily Bodnar assumed coverage of Artiva Biotherapeutics with a Buy rating and $12 price target. The company's primary asset, AB-101, a nongenetically modified natural killer cell therapy being evaluated in various B-cell driven autoimmune diseases in combination with anti-CD20 monoclonal antibodies has potential to establish itself as a safe, efficacious, and outpatient-accessible treatment, the analyst tells investors in a research note. The firm sees significant share upside potential if initial safety and translational data in B-cell driven autoimmune diseases delivered by the end of 2025 and longer follow-up efficacy data in the first half of 2025 from the company's various Phase 1/2 studies are positive.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ARTV

Unlock Now

ARTV Should I Buy

ARTV Should I Buy

Should You Buy Artiva Biotherapeutics Inc (ARTV) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch